Form 8-K - Current report:
SEC Accession No. 0001493152-24-048292
Filing Date
2024-12-02
Accepted
2024-12-02 16:05:26
Documents
20
Period of Report
2024-11-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 42772
2 ex10-1.htm EX-10.1 4284
3 ex10-1_001.jpg GRAPHIC 447204
4 ex10-1_002.jpg GRAPHIC 281755
5 ex10-1_003.jpg GRAPHIC 134614
6 ex10-1_004.jpg GRAPHIC 339453
7 ex10-1_005.jpg GRAPHIC 28770
  Complete submission text file 0001493152-24-048292.txt   1964737

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE lixt-20241129.xsd EX-101.SCH 3519
9 XBRL DEFINITION FILE lixt-20241129_def.xml EX-101.DEF 29971
10 XBRL LABEL FILE lixt-20241129_lab.xml EX-101.LAB 36548
11 XBRL PRESENTATION FILE lixt-20241129_pre.xml EX-101.PRE 26994
23 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5391
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 241519011
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)